Human Immunology News

Human Immunology News is an online publication and email newsletter for researchers studying the human immune system.

US FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic...

January 27, 2026

[Wugen, Inc.] Wugen, Inc. announced that it has received Breakthrough Therapy Designation from the US FDA for its investigational CAR-T cell therapy, Sofi-cel.

Ouro Medicines Receives US FDA Fast Track Designation for Gamgertamig in Immune Thrombocytopenia and Autoimmune Hemolytic Anemia

January 27, 2026

[Ouro Medicines,] Ouro Medicines announced that gamgertamig, the company’s BCMAxCD3 T cell engager antibody investigational candidate, has been granted US FDA Fast Track designation for development in the treatment of autoimmune hemolytic anemia and for immune thrombocytopenia.

Immunosuppressive Immune Microenvironment Landscapes in VISTA-High Gastric Cancer

January 27, 2026

[British Journal of Cancer] Researchers conducted multiplex immunohistochemistry on tumor samples from 172 patients to characterize the immune landscape of the V-domain Ig-containing suppressor of T cell activation (VISTA)-high tumor microenvironment.

A Single-Cell Atlas of Bone Marrow B Cells Reveals Defective Central B-Cell Tolerance in Immune Thrombocytopenia

January 27, 2026

[Blood] The authors investigated how central B cell tolerance mechanisms affect autoantibody production in immune thrombocytopenia.

Vδ1 T-Cell Subset Appears to Be Responsive to PD-1 Blockade Therapy and Is Associated with Survival in Melanoma

January 23, 2026

[Journal for Immunotherapy of Cancer] Researchers nvestigated the phenotype, functionality and t cell receptor repertoire of peripheral blood and tumor-infiltrating γδ T cells in patients with late-stage melanoma receiving anti-PD-1 therapy, in order to further dissect their role and potential for exploitation in cancer immunotherapy.

Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer

January 23, 2026

[Cancer Immunology Research] Using hyperplexed imaging and the spatial analysis, researchers discovered that ataxia telangiectasia and Rad3-related inhibitor responses were associated with significant increases in both intra- and peritumoral T cell infiltration, particularly in PD1+ CD8+ T cells.

Beyond αβ T Cells: Unlocking the Potential of Diverse Immune Cells in CAR Modification

January 23, 2026

[Clinical Science] Scientists are investigating alternative CAR-engineered immune cells, including CAR-NK cells, CAR-γδ T cells, and CARmacrophages, which offer distinct advantages over conventional CAR-T therapy.

IL-21 Mediates Crosstalk between T Cells and NK Cells during the Remission of Type 1 Diabetes

January 21, 2026

[Nature Metabolism] Using single-cell RNA sequencing integrated with cross-sectional and longitudinal analyses in patients with type 1 diabetes, scientists showed that CD226+ NK cell frequency correlates with disease progression.

How Crosstalk at the Immune Synapse Shapes T Cell and Dendritic Cell Biologys

January 21, 2026

[Nature Reviews Immunology] The authors discuss our current understanding of the bidirectional T cell–dendritic cell crosstalk that occurs at the IS and its relevance for immune responses and immunotherapies.

Unraveling the Effects and Characteristics of Proliferating Tumor and Cytotoxic T Cells in Colorectal Cancer

January 20, 2026

[Clinical Cancer Research] The authors investigated characteristics and prognostic significance of proliferating tumor and cytotoxic T cells. High MKI67+ tumor cell percentage was associated with better cancer-specific survival, an antitumorigenic immune microenvironment, downregulation of epithelial–mesenchymal transition, and upregulation of MYC signaling.

Impaired Function of Vγ9Vδ2 T Cells in Frail Elderly

January 20, 2026

[Immunity & Ageing] Researchers investigated the transcriptomic, phenotypic, and functional alterations of Vγ9Vδ2 T cells in frail older adults to elucidate their potential role in frailty-associated immune dysregulation.

Nous-209 Neoantigen Vaccine for Cancer Prevention in Lynch Syndrome Carriers: A Phase 1b/2 Trial

January 20, 2026

[Nature Medicine] Scientists presented the results from cohort 1 of a Phase Ib/II single-arm trial of Nous-209 for cancer interception in Lynch syndrome carriers.

Each issue of Human Immunology News provides up-to-date coverage of the latest news in immunology research performed using human cells or subjects. Our expert editors hand-pick recent research papers and review articles from relevant high-impact peer-reviewed journals on topics including immunotherapy, autoimmunity, adaptive, and innate immunity in humans. We also feature news on clinical trials, award announcements, and funding opportunities.